PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Zoledronic Acid

Drugs in development · updated 30 October 2026

Zoledronic Acid: clinical trials and development status

Other names and codes: Zoledronate, Reclast, Zometa

NLM verified identityApproved in the US (FDA)Authorised in the EU (EMA) since 20 March 2001

As of 30 October 2026 Zoledronic Acid is in 18 active clinical trials (recruiting or ongoing, phases I–III) for 33 diseases. The most advanced phase is III.

18Active trials
IIIMost advanced phase
33Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Zoledronic Acid and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov. Showing 30 of 33 diseases.

DiseaseMost advanced phaseActive trialsReference trial
OsteosarcomaIII3NCT00470223
SarcomaIII2NCT00470223
Giant-cell tumor of boneIII1NCT03295981
Prostatic NeoplasmsII–III1NCT00268476
Ewing sarcomaI–II2NCT06625190
NeuroblastomaI–II2NCT06625190
OsteoporosisII2NCT04608630
RhabdomyosarcomaI–II2NCT06625190
AdenocarcinomaI–II1NCT06759064
Alveolar soft part sarcomaI–II1NCT06625190
AscitesI–II1NCT06759064
Breast neoplasmI–II1NCT06374459
ChordomaI–II1NCT06625190
Clear-cell sarcomaI–II1NCT06625190
Congenital dyserythropoietic anemiaI–II1NCT07471516
Critical illnessII1NCT04608630
Desmoplastic small-round-cell tumorI–II1NCT06625190
MyoepitheliomaI–II1NCT06625190
Nerve sheath neoplasmsI–II1NCT06625190
OsteomyelitisII1NCT07668583
Pancreatic neoplasmII1NCT03073785
Rhabdoid tumorI–II1NCT06625190
Stomach neoplasmI–II1NCT06759064
Synovial sarcomaI–II1NCT06625190
Wilms TumorI–II1NCT06625190
Acute myeloid leukemiaI1NCT02508038
ChondrosarcomaI1NCT03173976
Chronic renal insufficiencyI1NCT07741136
Hodgkin lymphomaI1NCT02508038
Myelodysplastic SyndromesI1NCT02508038

Everything on Zoledronic Acid

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch